Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Aesthetic Expansion | Evolus enters the hyaluronic acid dermal filler market with FDA-approved Evolysse, potentially increasing its addressable market by 78% to $6 billion |
Financial Milestones | Explore Evolus's journey to profitability, with Q3 2024 revenue of $61 million and ambitious targets of $700 million revenue by 2028 |
Market Dynamics | Delve into the "Ozempic effect" driving filler demand and how Evolus's cold cross-linking technology positions it against established competitors |
Growth Trajectory | Analysts project $16-$27 price targets, with fillers expected to contribute 8-10% of 2025 revenue, signaling potential for significant market expansion |
Metrics to compare | EOLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEOLSPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.2x | 6.4x | −0.5x | |
PEG Ratio | −0.70 | 0.09 | 0.00 | |
Price/Book | −87.0x | 1.4x | 2.6x | |
Price / LTM Sales | 2.1x | 1.3x | 3.3x | |
Upside (Analyst Target) | 174.4% | 90.1% | 43.5% | |
Fair Value Upside | Unlock | 28.8% | 6.3% | Unlock |